The authors showed that FAM46C overexpression makes DU145 prostate cancer cells more sensitive to docetaxel treatment and, accordingly, that FAM46C down-modulation in the 22RV1 prostate cancer cell model makes them less sensitive to docetaxel administration. The gene discussed is TENT5C; the disease is prostate carcinoma.